2020-10-21T10:14:33-05:00 2019-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2019-01-01 311667995 CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY % LINDA JENSEN CFO CONQ 5714831700 2318 MILL ROAD Suite 800 ALEXANDRIA VA 22314 LINDA JENSEN CFO 5714831300 2020-10-20 true Marc Berger P01871563 7038930600 73.53.153.141 54621820202955000001 2020-10-21 P F80C4C4CE64063363A32333BB37C43EAD2BBFD59 F80C4C4CE64063363A32333BB37C43EAD2BBFD59 2019 2021-01-29 14:40:06Z CLIFFORD HUDIS MD 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 33401732 false X WWW.CONQUER.ORG X 1999 VA CONQUERING CANCER WORLDWIDE BY FUNDING BREAKTHROUGH RESEARCH AND SHARING CUTTING-EDGE KNOWLEDGE. CONQUER CANCER'S VISION IS A WORLD FREE FROM THE FEAR OF CANCER. 16 15 0 156 522500 269300 31933505 27209762 0 522500 1229060 2692338 4425 26046 33166990 30450646 15819973 15020244 0 0 0 0 121000 222000 4214530 7943766 9672350 23884739 24914594 9282251 5536052 74547914 89666380 4353781 7196521 70194133 82469859 X CONQUER CANCER , THE ASCO FOUNDATION, FUNDS RESEARCH INTO EVERY FACET OF CANCER TO BENEFIT EVERY PATIENT, EVERYWHERE. IN 1964, SEVEN ONCOLOGISTS CREATED THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), NOW A GLOBAL NETWORK OF NEARLY 45,000 CANCER PROFESSIONALS. AS ASCO'S FOUNDATION, CONQUER CANCER HELPS TURN SCIENCE INTO A SIGH OF RELIEF FOR PATIENTS AROUNDS THE WORLD BY SUPPORTING GROUNDBREAKING RESEARCH AND EDUCATION ACROSS CANCER'S FULL CONTINUUM. false false 6690010 6690010 PROFESSIONAL EDUCATION - CONQUER CANCER HELPS ONCOLOGY PROFESSIONALS WORLDWIDE STAY UP TO DATE ON THE LATEST DEVELOPMENTS AND DISCOVERIES IN CANCER KNOWLEDGE. CONQUER CANCER SUPPORTS THE EFFORTS OF ASCO TO PROVIDE EDUCATION PROGRAMS IN THE US AND INTERNATIONALLY WHICH PROMOTE THE VITAL EXCHANGE OF IDEAS THAT LEAD TO WORLD-CLASS CARE, EVERYWHERE. FUNDS FROM CONQUER CANCER ARE USED TO SUPPORT ASCO'S COMPREHENSIVE SCIENTIFIC AND EDUCATIONAL PROGRAMS THROUGH BOTH LIVE MEETINGS AND PRINT AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC PROGRAMS SUPPORTED BY CONQUER CANCER AND PRESENTED TO THE PUBLIC IN 2019 INCLUDE THE FOLLOWING: * THE ASCO ANNUAL MEETING FEATURED NEARLY 265 EDUCATIONAL AND SCIENTIFIC SESSIONS. MORE THAN 5,000 ABSTRACTS WERE PRESENTED OR PUBLISHED. THE ASCO ANNUAL MEETING IS CONSIDERED THE PREMIER EDUCATIONAL AND SCIENTIFIC EVENT IN THE ONCOLOGY COMMUNITY AND ATTRACTS MORE THAN 40,000 ATTENDEES WORLDWIDE. THE MEETING OFFERS HEALTHCARE PROFESSIONALS PROVIDING ONCOLOGY CARE AN IMPORTANT OPPORTUNITY TO COME TOGETHER TO EXPLORE THE LATEST ADVANCES IN SCIENCE; CONTEXTUALIZE RECENT DISCOVERIES AND OPTIMIZE TREATMENT AND RESEARCH STRATEGIES; FRAME AND DISCUSS MAJOR CONTROVERSIES IN THE FIELD; AND NETWORK WITH PEERS IN AN ENVIRONMENT CHARGED WITH THE EXCITEMENT OF A COMMON GOAL: PROGRESS TOWARD BETTER OUTCOMES FOR PATIENTS. * GASTROINTESTINAL CANCERS (GI) SYMPOSIUM - THE ANNUAL GI SYMPOSIUM IS THE PREMIERE MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETING. THE GI SYMPOSIUM GIVES HEALTHCARE PROVIDERS ACROSS MULTIPLE DISCIPLINES AND PROFESSIONS THE OPPORTUNITY TO RECEIVE CRITICAL UPDATES AND RECOMMENDATIONS TO IMPROVE THE CARE OF PATIENTS WITH GI CANCERS. THE SYMPOSIUM IS JOINTLY DEVELOPED BY A COMMITTEE WITH REPRESENTATIVES FROM THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE (AGA INSTITUTE), THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO), AND THE SOCIETY OF SURGICAL ONCOLOGY (SSO), WITH ADDITIONAL CONTENT ADVISORS FROM THE SOCIETY OF THORACIC SURGEONS (STS) AND THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD). * GENITOURINARY CANCERS (GU) SYMPOSIUM - THE ANNUAL GU SYMPOSIUM IS THE PREEMINENT GENITOURINARY ONCOLOGY EVENT, ADDRESSING THE MULTIDISCIPLINARY NEEDS OF PHYSICIANS AND OTHER MEMBERS OF THE CANCER CARE AND RESEARCH COMMUNITY WHO DIAGNOSE, TREAT, AND STUDY GENITOURINARY MALIGNANCIES. THE GU SYMPOSIUM PROVIDES THE LATEST STRATEGIES IN SCREENING, DIAGNOSIS, TREATMENT, MANAGEMENT AND CONTROVERSIES IN THE FIELD OF GENITOURINARY CANCERS. THE SYMPOSIUM IS JOINTLY DEVELOPED BY COMMITTEES WITH REPRESENTATIVES FROM THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO), AND THE SOCIETY OF UROLOGIC ONCOLOGY (SUO). * BEST OF ASCO - WITH THE FIELD OF CANCER CARE CONSTANTLY EVOLVING AND EXPANDING, THE BEST OF ASCO MEETINGS BRING TOGETHER EXPERT FACULTY TO SYNTHESIZE THE MOST IMPORTANT RESEARCH AND CLINICAL DEVELOPMENTS PRESENTED AT THE ASCO ANNUAL MEETING AND TO DISCUSS PRACTICAL APPLICATIONS FOR PATIENT CARE. A PANEL OF ASCO EXPERTS SELECTS ABSTRACTS THAT HIGHLIGHT THE IMPORTANT SCIENTIFIC INFORMATION TO CREATE THE BEST OF ASCO MEETING PROGRAM. THIS PROGRAM PROVIDES ACCESS TO THE MOST CUTTING-EDGE, PRACTICE-CHANGING RESEARCH PRESENTED AT THE MEETING IN A RESPONSIBLE, PEER-REVIEWED MANNER. * SUPPORTIVE CARE IN ONCOLOGY SYMPOSIUM - THE SUPPORTIVE CARE IN ONCOLOGY SYMPOSIUM FOCUSES ON THE CONTINUUM OF SYMPTOM MANAGEMENT THROUGH ALL STAGES OF CANCER THERAPY. THE PROGRAM IS DESIGNED TO OFFER INSIGHTS INTO THE SCIENCE AND RESEARCH IN SUPPORTIVE CARE COMBINED WITH PRACTICAL GUIDANCE REGARDING IMPLEMENTATION OF BEST PRACTICES AND EVIDENCE-BASED CARE. THE PROGRAM INCORPORATES ABSTRACTS WITH THE LATEST FINDINGS, CHALLENGING CASES, AND AMPLE OPPORTUNITY FOR EXTENDED QUESTION AND ANSWER PERIODS AND MODERATED DISCUSSIONS THROUGHOUT. THE RESULT IS AN ENVIRONMENT WHERE EDUCATION AND SCIENCE OF SUPPORTIVE CARE ACROSS THE CONTINUUM COME TOGETHER TO MEET THE PRESSING NEEDS OF SUPPORTIVE CARE AND ONCOLOGY SPECILISTS ALIKE. THREE LEADING MEDICAL SPECIALITY SOCITIES COSPONSOR THE SUPPORTIVE CARE IN ONCOLOGY SYMPOSIUM: THE AMERICAN ACADEMY OF HOSPICE AND PALLIATIVE MEDICINE (AAHPM), THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), AND THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO). *QUALITY CARE SYMPOSIUM - THE ASCO QUALITY CARE SYMPOSIUM PROVIDES A FORUM TO SHARE THE LATEST STRATEGIES AND METHODS FOR QUANTIFICATION OF PATIENT EXPERIENCE, PROVIDER EFFICIENCY, CLINICAL OUTCOMES, AND QUALITY AND SAFETY IN THE CANCER CARE FIELD. THE SYMPOSIUM BRINGS TOGETHER LEADERS IN THE FIELD TO SHARE STRATEGIES AND METHODS FOR MEASURING AND IMPROVING THE QUALITY OF CANCER CARE AND DISSEMINATES INFORMATION ON THE IMPROVEMENT OF THE QUALITY OF PATIENT AND SURVIVOR CARE THROUGH IMPLEMENTATION SCIENCE AND METHODS FOR QUANTIFICATION OF PATIENT EXPERIENCES, PROVIDER EFFICIENCY, CLINICAL OUTCOMES, SAFETY, AND VALUE. *IMMUNO-ONCOLOGY SYMPOSIUM - THE ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM EXPLORES CLINICAL AND TRANSLATIONAL RESEARCH IN IMMUNO-ONCOLOGY AND IMPLICATIONS FOR PATIENT CARE. THE SYMPOSIUM FACILITATES IMPORTANT EDUCATIONAL AND SCIENTIFIC DIALOGUES ON CLINICAL DEVELOPMENTS ACROSS DISEASE SITES IN THE RAPIDLY ADVANCING FIELD OF IMMUNO-ONCOLOGY, AND HELPS MEET THE WIDESPREAD NEED FOR EDUCATION IN RESPONSE TO A PARADIGM SHIFT IN CANCER TREATMENT THAT TARGETS THE IMMUNE SYSTEM RATHER THAN THE TUMOR. THE SYMPOSIUM IS DEVELOPED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) AND THE SOCIETY FOR THE IMMUNOTHERAPY OF CANCER (SITC). *ASCO/AACR METHODS IN CLINICAL CANCER RESEARCH WORKSHOP - SINCE 1996, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC. (ASCO) AND THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) HAVE JOINTLY SPONSORED THE METHODS IN CLINICAL CANCER RESEARCH WORKSHOP. THE WORKSHOP OFFERS AN INTENSIVE LEARNING OPPORTUNITY FOR CLINICAL FELLOWS AND CLINICALLY-ORIENTED JUNIOR FACULTY RESEARCHERS IN ALL ONCOLOGY SUBSPECIALTIES. THE WORKSHOP COVERS THE ESSENTIALS OF EFFECTIVE CLINICAL TRIAL DESIGNS OF THERAPEUTIC INTERVENTIONS IN THE TREATMENT OF CANCER. HIGHLIGHTS OF PRINT AND ELECTRONIC PROFESSIONAL EDUCATION MATERIALS SUPPORTED BY CONQUER CANCER AND AVAILABLE TO THE PUBLIC IN 2019 INCLUDE THE FOLLOWING: *MEETING LIBRARY- ASCO'S MEETING LIBRARY IS A ONE-STOP LOCATION TO ACCESS ABSTRACTS, EDUCATIONAL BOOK MANUSCRIPTS, VIDEOS, SLIDES, AND POSTERS PRESENTED AT ASCO'S MEETINGS. ASCO'S MEETING LIBRARY IS AN INTEGRAL INFORMATIONAL AND EDUCATIONAL RESOURCE FOR ASCO MEMBERS, OTHER PHYSICIANS, PEOPLE WITH CANCER, AND THE GENERAL PUBLIC. THE ASCO MEETING LIBRARY BUNDLE INCLUDES THE FOLLOWING PRODUCTS: ABSTRACTS: ASCOS COMPREHENSIVE ONLINE DATABASE OF ONCOLOGY-RELATED RESEARCH ABSTRACTS FROM THE PREVIOUS 5 YEARS. INCLUDES LINKS TO RELATED PRESENTATIONS AND ADDITIONAL ABSTRACTS. VIDEOS AND SLIDES: ASCO VIDEOS AND SLIDES USE THE LATEST TECHNOLOGY TO DELIVER NEARLY 47,000 ORAL PRESENTATIONS AND ORAL ABSTRACTS FROM ASCO MEETINGS AND SYMPOSIA DATING BACK TO 2011. THE MOST COMPREHENSIVE COLLECTION OF ONCOLOGY-RELATED MEDIA IS AVAILABLE ONLINE FOR PHYSICIANS, RESEARCHERS, AND PATIENTS. MEETING POSTERS: POSTERS FROM GENERAL POSTER AND POSTER DISCUSSION SESSIONS FOR ASCO ANNUAL MEETING, GASTROINTESTINAL CANCERS SYMPOSIUM, GENITOURINARY CANCERS SYMPOSIUM, ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM, CANCER SURVIVORSHIP SYMPOSIUM, ASCO QUALITY CARE SYMPOSIUM, AND THE SUPPORTIVE CARE IN ONCOLOGY SYMPOSIUM. ARCHIVED CONTENT IS AVAILABLE FOR MEETINGS NO LONGER OFFERED. *ASCO CLINICAL GUIDELINES MOBILE APPLICATION - ASCO DEVELOPS AND PUBLISHES CLINICAL PRACTICE GUIDELINES TO SERVE AS A GUIDE FOR DOCTORS AND OUTLINE APPROPRIATE METHODS OF TREATMENT AND CARE. THE GUIDELINES CAN ALSO ADDRESS SPECIFIC DISEASE-ORIENTED CLINICAL SITUATIONS, AS WELL AS USE OF APPROVED MEDICAL PRODUCTS, PROCEDURES, AND TESTS. THE ASCO CLINICAL PRACTICE GUIDELINES MOBILE APPLICATION IS DESIGNED TO MAKE ASCO GUIDELINES MORE USER FRIENDLY BY PROVIDING ACCESS AT THE BEDSIDE AND/OR IN CLINIC BY MEMBERS OF THE ONCOLOGY CARE TEAM, WITH THE ULTIMATE RESULT OF IMPROVING PATIENT CARE BASED ON ESTABLISHED SCIENCE AND THE LATEST RESEARCH. THE MOBILE APPLICATION IS AVAILABLE FOR THE APPLE IOS AND ANDROID OPERATING SYSTEMS, ACCESSIBLE BY SMARTPHONES AND TABLETS. INTERACTIVE TOOLS ARE ALSO INCLUDED WITHIN SOME GUIDELINES. 10853950 6838475 RESEARCH - THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER HAS A DEMONSTRATED TRACK RECORD IN SUPPORTING THE EARLY CAREER DEVELOPMENT OF ONCOLOGY RESEARCHERS, INCLUDING IDENTIFYING AND NURTURING THOSE WHO HAVE BECOME NOTABLE LEADERS AND INNOVATORS IN THE FIELD. PAST GRANT RECIPIENTS HAVE BECOME HEADS OF LARGE CANCER INSTITUTIONS AND PRESIDENTS OF MAJOR ONCOLOGY SOCIETIES, AS WELL AS GUIDED THE NATIONAL ONCOLOGY CONVERSATION THROUGH SERVICE ON BOARDS AND COMMITTEES. ADDITIONALLY, PAST RECIPIENTS HAVE ALSO INVESTED IN THE NEXT GENERATION OF YOUNG INVESTIGATORS BY SERVING AS MENTORS TO NEWLY CHOSEN CONQUER CANCER GRANTEES. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. EACH YEAR, CONQUER CANCER FUNDS AND AWARDS MULTIPLE RESEARCH GRANTS DESIGNED TO HELP ATTRACT AND RETAIN THE BEST SCIENTIFIC MINDS IN CANCER RESEARCH AND TO SUPPORT THEIR EFFORTS. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $126 MILLION IN CANCER RESEARCH GRANTS TO OVER 2,100 RECIPIENTS IN 75 COUNTRIES. HIGHLIGHTS OF 2019 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE: ADVANCED CLINICAL RESEARCH AWARD (ACRA) - $450,000 PROVIDED ONE (1) THREE-YEAR AWARD TO SUPPORT A PHYSICIAN-SCIENTIST COMMITTED TO PERFORMING ORIGINAL, CLINICAL CANCER RESEARCH IN BREAST CANCER. THIS RESEARCH MUST HAVE A PATIENT-ORIENTED FOCUS, INCLUDING A CLINICAL RESEARCH STUDY AND/OR TRANSLATIONAL RESEARCH INVOLVING HUMAN SUBJECTS. CAREER DEVELOPMENT AWARD (CDA) - $3,200,000 PROVIDED SIXTEEN(16) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH OF CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS. YOUNG INVESTIGATOR AWARD (YIA) - $3,800,000 PROVIDED SEVENTY-SIX (76) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY PROVIDING FUNDS TO PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT. GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD - $300,000 PROVIDED SIX (6) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS CONDUCTING RESEARCH IN LOW RESOURCE SETTINGS ON SCIENTIFIC QUESTIONS SPECIFIC TO THOSE SETTINGS, WITH THE POTENTIAL TO OFFER "REVERSE INNOVATION" INSIGHTS TO INFLUENCE ONCOLOGY PRACTICE IN A WIDE RANGE OF RESOURCE SETTINGS, BY INVESTIGATORS IN HIGH RESOURCE SETTINGS ON ISSUES IN RESOURCE-LIMITED SETTINGS, OR COLLABORATIVE RESEARCH BETWEEN INVESTIGATORS IN BOTH HIGH AND LOW RESOURCE SETTINGS ON QUESTIONS OF SHARED CONCERN. THE GOAL FOR THE GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD IS TO ENCOURAGE AND PROMOTE QUALITY RESEARCH IN GLOBAL ONCOLOGY, AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS. THE JAMES B. NACHMAN JUNIOR FACULTY AWARD IN PEDIATRIC ONCOLOGY WAS ESTABLISHED IN MEMORY OF JAMES B. NACHMAN, MD, AN INTERNATIONALLY RENOWNED PEDIATRIC CANCER EXPERT AND PEDIATRICS PROFESSOR. HE CHAIRED SEVERAL CHILDREN'S ONCOLOGY GROUP NATIONAL STUDY COMMITTEES AND WAS AN AUTHORITY IN THE MEDICAL MANAGEMENT OF CHILDHOOD CANCERS, ESPECIALLY LEUKEMIA AND LYMPHOMA. $3,000 PROVIDED FOR ONE JUNIOR FACULTY MEMBER WITH THE HIGHEST SCORING ABSTRACT IN PEDIATRIC ONCOLOGY. MERIT AWARDS- $195,000 PROVIDED FOR ONE-HUNDRED NINETY-FOUR (194)MERIT AWARDS WHICH PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AND INTERACT WITH OTHER CLINICAL CANCER INVESTIGATORS AT ASCO SCIENTIFIC MEETINGS AND DISEASE SPECIFIC SYMPOSIA. MEDICAL STUDENT ROTATION FOR UNDERREPRESENTED POPULATIONS (MSR)- $85,000 PROVIDED FOR TEN (10) MEDICAL STUDENT ROTATIONS. THE MSR PROVIDES A 4-WEEK CLINICAL OR CLINICAL RESEARCH ROTATION FOR U.S. MEDICAL STUDENTS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE WHO ARE INTERESTED IN PURSUING ONCOLOGY AS A CAREER AND ALLOWS THEM TO GAIN KNOWLEDGE AND EXPERIENCE IN THE AREAS OF CLINICAL CANCER CARE AND RESEARCH. A MENTORING COMPONENT IS INCLUDED IN THE MSR WHEREBY AWARD RECIPIENTS ARE PAIRED WITH A CLINICAL ONCOLOGIST WHO PROVIDES ACADEMIC AND CAREER GUIDANCE, BOTH DURING AND FOLLOWING THE ROTATION EXPERIENCE. RESIDENT TRAVEL AWARD FOR UNDERREPRESENTED POPULATIONS - $9,000 PROVIDED FOR SIX (6) RESIDENT TRAVEL AWARDS (RTA). THE RTA PROVIDES FINANCIAL SUPPORT FOR RESIDENTS FROM UNDERREPRESENTED POPULATIONS TO ATTEND THE ASCO ANNUAL MEETING. ATTENDING THE ASCO ANNUAL MEETING GIVES PHYSICIAN RESIDENTS INTERESTED IN A CAREER IN ONCOLOGY THE OPPORTUNITY TO MEET ONCOLOGISTS AND TO LEARN MORE ABOUT CAREER OPTIONS IN THE FIELD. 137390 137390 QUALITY AND ACCESS TO CARE - REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH QUALITY CANCER CARE IS AVAILABLE TO EVERYONE. CONQUER CANCER IS KEENLY AWARE OF THE POTENTIALLY FATAL DIVIDE BETWEEN THOSE WITH ACCESS TO THE FRUITS OF RESEARCH AND TIMELY CARE AND THOSE WITHOUT. WE SEEK TO CONFRONT THESE DISPARITIES AND IMPROVE THE OUTLOOK FOR EVERY PERSON TOUCHED BY CANCER BY SUPPORTING PROGRAMS THAT INCREASE ACCESS TO CARE IN ALL COMMUNITIES, INCLUDING THOSE UNDERSERVED. THE QUALITY AND ACCESS TO CARE PROGRAMS AND INITIATIVES SUPPORTED BY CONQUER CANCER IN 2019 INCLUDE THE FOLLOWING: DIVERSITY IN ONCOLOGY INITIATIVE - THE CONQUER CANCER GRANTS AND AWARDS PROGRAM PROVIDES FUNDING FOR DIFFERENT TYPES OF AWARD OPPORTUNTIES FOR ONCOLOGY FELLOWS, CLINICAL PRACTICES, AND INTERNATIONAL RESEARCHERS. ONE OF THE PROGRAMS OFFERED THROUGH CONQUER CANCER IS THE DIVERSITY IN ONCOLOGY INITIATIVE. THE DIVERSITY IN ONCOLOGY INITIATIVE WAS STRUCTURED TO FACILIATE THE RECRUITMENT AND RETENTION OF INDIVIDUALS FORM POPULATIONS UNDERREPRESENTED IN MEDICINE TO CANCER CAREERS, WITH PARTICULAR ATTENTION TO THE DEVELOPMENT OF CLINICAL PRACTITIONERS AND INVESTIGATORS. THE DIVERSITY IN ONCOLOGY PROGRAM CONSISTS OF AWARD OPPORTUNITIES FOR MEDICAL STUDENTS AND RESIDENTS WHO SELF-IDENTITY AS BEING MEMBERS OF UNDERREPRESENTED POPULATIONS. TWO AWARD OPPORTUNITIES ARE AVAILABLE: THE MEDICAL STUDENT ROTATION FOR UNDERREPRESENTED POPULATIONS (MSR) AND THE RESIDENT TRAVEL AWARD FOR UNDERREPRESENTED POPULATIONS. THE MSR PROVIDES A 4-WEEK CLINICAL OR CLINICAL RESEARCH ROTATION FOR U.S. MEDICAL STUDENTS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE WHO ARE INTERESTED IN PURSUING ONCOLOGY AS A CAREER AND ALLOWS THEM TO GAIN KNOWLEDGE AND EXPERIENCE IN THE AREAS OF CLINICAL CANCER CARE AND RESEARCH. A MENTORING COMPONENT IS INCLUDED IN THE MSR WHEREBY AWARD RECIPIENTS ARE PAIRED WITH A CLINICAL ONCOLOGIST WHO PROVIDES ACADEMIC AND CAREER GUIDANCE, BOTH DURING AND FOLLOWING THE ROTATION EXPERIENCE. $85,000 PROVIDED FOR TEN (10) MEDICAL STUDENT ROTATIONS. THE RESIDENT TRAVEL AWARD PROVIDES FINANCIAL SUPPORT TO RESIDENTS FROM UNDERREPRESENTED POPULATIONS TO ATTEND THE ASCO ANNUAL MEETING. ATTENDING THE ASCO ANNUAL MEETING GIVES PHYSICIAN RESIDENTS INTERESTED IN A CAREER IN ONCOLOGY THE OPPORTUNITY TO MEET ONCOLOGISTS AND TO LEARN MORE ABOUT CAREER OPTIONS IN THE FIELD. $9,000 PROVIDED FOR SIX (6) RESIDENT TRAVEL AWARDS. *QUALITY TRAINING PROGRAM - AS THE LEADING ONCOLOGY QUALITY IMPROVEMENT (QI) COURSE, ASCO'S QUALITY TRAINING PROGRAM EMPOWERS PRACTICE TEAMS TO IMPROVE CLINICAL CARE AND OPERATIONAL PERFORMANCE BY TEACHING TEAMS HOW TO BALANCE QUALITY IMPROVEMENT PROJECTS WITH DEMANDING SCHEDULES AND COMPETING PRIORITIES. CONTENT HAS BEEN DEVELOPED SPECIFICALLY FOR ONCOLOGY PRACTICE TEAMS AND INCLUDES ACCESS TO RENOWNED FACULTY AND COACHES DURING FIVE FOCUSED DAYS OF IN-PERSON LEARNING. DURING THOSE FIVE DAYS, PRACTICE TEAMS ATTEND THREE SESSIONS, WHICH INCLUDE SEMINARS, CASE EXAMPLES, ADN SMALL GROUP EXERCISES. LEARNING CONTINUES THROUGHOUT THE SIX-MONTH COURSE, INCLUDING REMOTE COACHING SESSIONS AS NEEDED. EACH TEAM WILL TAKE ITS QUALITY IMPROVEMENT KNOWLEDGE AND SKILLS TO ANOTHER LEVEL, ACCELERATING CHANGE AND IMPROVEMENT. TEAMS WILL WORK ON A PROBLEM OF THEIR OWN CHOOSING, WHICH COULD RANGE FROM IMPROVING CARE COORDINATION OR PATIENT SAFETY TO A SPECIFIC ORAL CHEMOTHERAPY PROJECT. 1354369 1354369 PATIENT EDUCATION & INFORMATION 1354369 1354369 19035719 true true false false false false false false false true false false false false false true true true false false true true true true true false false true true true false false false false false false false false true true false false false true false false false true 21 0 true 0 true true true false false false false true true false false false false false false X 16 15 true false false false false true true true true false false true true true true true true false false false AL AK AZ AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X LINDA JENSEN CFO 5714831320 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 Clifford Hudis MD FAC CEO 7.5 30.0 X X 0 898194 24233 LINDA JENSEN CPA CFO 7.5 30.0 X 0 401924 38536 Nancy Daly MS MPH EXEC VP & CHIEF PHILAN OFFICER 36.5 1.0 X 0 387673 38537 Thomas Roberts Jr M Chair 1.0 0.0 X X 0 0 0 Sandra Swain MD FACP Treasurer 1.0 0.0 X X 0 0 0 Claire A Huang Secretary 1.0 0.0 X X 0 0 0 Alexander W Casdin Board Member 1.0 0.0 X 0 0 0 Howard A Burris III Board Member 1.0 0.0 X 0 0 0 Thomas Marsland MD F Board Member 1.0 0.0 X 0 0 0 Lawrence H Einhorn M Board Member 1.0 0.0 X 0 0 0 W Charles Penley MD Board Member 1.0 0.0 X 0 0 0 Raj Mantena RPh Board Member 1.0 0.0 X 0 0 0 Robert Mayer MD FASC Board Member 1.0 0.0 X 0 0 0 Margaret Tempero MD Board Member 1.0 0.0 X 0 0 0 Steven Rosen MD FACP Board Member 1.0 0.0 X 0 0 0 Gerald J McDougall Board Member 1.0 0.0 X 0 0 0 Susan L Cohn MD FAS Board Member 1.0 0.0 X 0 0 0 Riccardo Braglia Board Member 1.0 0.0 X 0 0 0 Craig R Nichols MD FA Board Member 1.0 0.0 X 0 0 0 0 1687791 101306 0 false true false TRUE NORTH INC 630 3RD AVENUE 12TH FLOOR NEW YORK NY 10017 FUND. MESS & STRAT. 886500 STRATUSLIVE 6465 COLLEGE PARK SQUARE SUITE 400 VIRGINIA BEACH VA 23464 DONORMGMT IT SERV. 220309 2 7015 736500 1196282 4914000 20355965 1995522 27209762 ADVERTISING 900009 522500 522500 522500 2667684 2667684 0 0 0 0 0 2895613 2870959 24654 24654 24654 106173 1196282 80127 26046 26046 0 0 0 0 0 0 0 30450646 522500 2718384 13574321 13574321 338100 338100 1107823 1107823 0 0 0 0 0 0 0 0 0 0 5926708 2603483 869662 2453563 6504 6504 41574 41574 0 222000 222000 33191 33191 525064 359722 75408 89934 0 160682 97995 34965 27722 1121784 45554 364287 711943 0 649286 473615 68816 106855 298050 199668 15960 82422 0 197221 53253 65784 78184 0 0 0 0 POSTAGE 227816 50991 4785 172040 PRINTING 385237 110155 7749 267333 OTHER EXPENSES 99233 21039 75660 2534 24914594 19035719 1664345 4214530 9246912 5649132 0 0 7889011 6312068 889 610 0 0 0 0 0 0 0 0 188502 297353 0 0 56118569 76413045 0 0 0 0 0 0 1104031 994172 74547914 89666380 458665 299017 2857504 3072066 1037612 3825438 0 0 0 0 0 0 0 0 0 0 0 0 4353781 7196521 X 35258849 40974084 34935284 41495775 70194133 82469859 74547914 89666380 5536052 6739674 X false true X true false X 29974390 23158842 29032906 31998377 27209762 141374277 0 0 29974390 23158842 29032906 31998377 27209762 141374277 39649136 101725141 833497 877067 908055 719934 2667684 6006237 269300 269300 0 147649814 0.68896 0.67671 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 17571755 8235901 2772005 839500 27740161 17114411 2133374 -964377 711653 17571755 10363214 6170675 1125396 544874 17114411 9169527 1364000 280187 450500 10363214 3968976 5417500 -94449 122500 9169527 1.00000 false false 0 0 X 37237256 6739674 6739674 30497582 33191 -80127 -46936 30450646 24961530 80127 80127 24881403 33191 33191 24914594 PART V, LINE 4 Permanently restricted net assets of donor-restricted endowment funds are preserved, absent explicit direction from the donor. Interest from the permanently restricted funds is intended to fund future research and/or educational awards. PART V, LINE 1A-1G ENDOWMENT FUNDS ARE BASED ON GAAP AND AGREE TO THE RESTRICTED FUNDS ON THE AUDITED FINANCIAL STATEMENTS. PART X, LINE 2 IN ACCORDANCE WITH GAAP, THE FOUNDATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WILL BE SUSTAINED AN EXAMINATION BY TAXING AUTHORITIES, BASED ON THE TECHNICAL MERITS OF THE POSITION. THE TAX BENEFITS RECOGNIZED IN THE FINANCIAL STATEMENTS FROM SUCH A POSITION ARE MEASURED BASED ON THE LARGEST BENEFIT THAT HAS A GREATER THAN 50% LIKELIHOOD OF BEING REALIZED UPON ULTIMATE SETTLEMENT. THE FOUNDATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. GENERALLY, THE FOUNDATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE DECEMBER 31, 2016. PART XII, LINE 4b FUNDRAISING EXPENSES $80,127 PART XI, LINE 2d FUNDRAISING EXPENSES $80,127 true East Asia and the Pacific Program Services Awards & Grants 46625 Europe (Including Iceland and Greenland) Program Services AWARDS & GRANTS 143800 North America Program Services AWARDS & GRANTS 471000 South America Program Services AWARDS & GRANTS 326600 Sub-Saharan Africa Program Services AWARDS & GRANTS 29880 South Asia Program Services AWARDS & GRANTS 57118 Middle East and North Africa Program Services AWARDS & GRANTS 2000 1077023 1077023 North America Career Development Award 200000 CHECK North America Career Development Award 200000 CHECK Central America and the Caribbean Career Development Award 200000 CHECK Central America and the Caribbean GLOBOL ONCOL 50000 CHECK Central America and the Caribbean GLOBAL ONCOL 50000 CHECK Europe (Including Iceland and Greenland) GLOBOL ONCOL 50000 CHECK South Asia INT'L INNOVATION 20000 CHECK South Asia INT'L INNOVATION 20000 CHECK Sub-Saharan Africa INT'L INNOVATION 20000 CHECK Central America and the Caribbean INT'L INNOVATION 20000 CHECK North America YOUNG INVEST 50000 CHECK Europe (Including Iceland and Greenland) YOUNG INVEST 50000 CHECK 12 PATIENT ADVOCATE East Asia and the Pacific 1 2200 CHECK PATIENT ADVOCATE Europe (Including Iceland and Greenland) 1 2200 CHECK PATIENT ADVOCATE Europe (Including Iceland and Greenland) 1 2200 CHECK PATIENT ADVOCATE Europe (Including Iceland and Greenland) 1 2200 CHECK PATIENT ADVOCATE Europe (Including Iceland and Greenland) 1 2200 CHECK PATIENT ADVOCATE Europe (Including Iceland and Greenland) 1 2200 CHECK PATIENT ADVOCATE Central America and the Caribbean 1 2200 CHECK PATIENT ADVOCATE North America 1 2200 CHECK PATIENT ADVOCATE South Asia 1 2200 CHECK PATIENT ADVOCATE South Asia 1 2200 CHECK PATIENT ADVOCATE Sub-Saharan Africa 1 2200 CHECK PATIENT ADVOCATE Sub-Saharan Africa 1 2200 CHECK PATIENT ADVOCATE Sub-Saharan Africa 1 2200 CHECK false false false false false false PART I, LINE 2: EXPLANATION: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CONQUER CANCER REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENT WITH THE APPROVED BUDGET. X X X X X X true FAIRCOM NEW YORK 12 WEST 27TH STREET 13TH FLOOR NEW YORK NY 10001 GENERAL false 618062 54000 564062 TRUE NORTH 630 3RD AVENUE 12TH FLOOR NEW YORK NY 10017 FUNDRAISING STRATEGY false 0 168000 -168000 618062 222000 396062 AL CA CO CT DC FL GA KS KY ME MD MA MI MS NV NH NJ NY NC ND OK OR PA RI SC TN UT WA WI RESEARCH DINNER 1010938 904765 106173 36703 43424 SEPTEMBER SALON 99689 99689 5 125656 125656 1236283 1130110 106173 36703 43424 80127 26046 FORM 990, SCHEDULE G, PART I, LINE 1 THE RETAINER FEES ARE PAID FOR THE WORK THAT FAIRCOM NY DOES ON MANAGING OUR ACCOUNT. THIS INCLUDES STRATEGY, COPY WRITING, LIST RECOMMENDATIONS, DATA ANALYSIS, ETC. THE OTHER FEES ARE FOR THE PRODUCTION OF THE ACTUAL MAILINGS THEMSELVES, POSTAGE, PRINTING, ACTUAL LIST RENTALS, ETC. TRUE NORTH PROVIDED DONOR STRATEGY CONSULTATION. true Cedars-Sinai Medical Center 8700 Beverly Blvd 1S35 Los Angeles CA 90048 951644600 501(C)(3) 450000 ACRA Columbia University Medical Center 630 West 168th Street New York NY 11042 135598093 501(C)(3) 700000 CDA, YIA Dana-Farber Cancer Institute 44 Binney St Boston MA 022155450 042263040 501(C)(3) 1050000 CDA, YIA Feinstein Institute Northwell Heath Monter Cancer Center Lake Success NY 11042 112673595 501(C)(3) 50000 YIA Fred Hutchinson Cancer Research Center 1100 Fairview Ave N Seattle WA 98109 237156071 501(C)(3) 150000 YIA Howard University 2400 Sixth Street NW Washington DC 20059 530204707 501(C)(3) 8500 MSR Icahn School of Medicine at Mount Sinai 1 Gustave L Levy Pl New York NY 100293294 136171197 501(C)(3) 100000 YIA Indiana University 420 University Boulevard Indianapolis IN 46202 356001673 501(C)(3) 200000 CDA Joan & Sanford I Weill Medical College of Cornell 525 East 68th Street New York NY 10065 131623978 501(C)(3) 165000 LIFE, YIA Johns Hopkins University 3400 N Charles Street Baltimore MD 212182608 520595110 501(C)(3) 450000 CDA, YIA Maine Medical Center 22 Bramhall Street Portland ME 041023175 010238552 501(C)(3) 50000 YIA Massachusetts General Hospital 55 Fruit Street Boston MA 02114 042697983 501(C)(3) 450000 CDA, YIA Mayo Clinic 200 1st street SW Rochester MN 55905 416011702 501(C)(3) 100000 YIA Morehouse School of Medicine 720 Westview Drive SW Atlanta GA 303101495 581438873 501(C)(3) 8500 MSR Ochsner Clinic Foundation 1514 Jefferson Highway BH 546 New Orleans LA 70121 720502505 501(C)(3) 50000 YIA Rhode Island Hospital 593 Eddy St Providence RI 029034923 050258809 501(C)(3) 50000 YIA Roswell Park Comprehensive Cancer Center Elm Carlton Streets Buffalo NY 14263 114140215 501(C)(3) 50000 YIA San Juan Bautista School of Medicine CAGUAS RQ 660361341 501(C)(3) 8500 MSR Sarah Cannon Research Institute 3322 West End AvenueSuite 900 Nashville TN 37203 201557751 501(C)(3) 50000 YIA Scripps Translational Science Institute 3344 North Torrey Pines Court Suit La Jolla CA 92307 330435954 501(C)(3) 50000 YIA Seattle Children's Hospital dba Seattle Children's Suite 300 Seattle WA 98115 910564748 501(C)(3) 50000 YIA Sloan Kettering Institute for Cancer Research 1275 York Avenue New York NY 10065 131624182 501(C)(3) 707847 CDA, YIA St Jude Children's Research Hospital 262 Danny Thomas Place Memphis TN 38105 620646012 501(C)(3) 150000 YIA Stanford University 800 Welch Road Stanford CA 94305 941156365 501(C)(3) 17000 MSR SUNY Upstate Medical University 750 E Adams Street Syracuse NY 13210 141438361 501(C)(3) 8500 MSR Texas Tech University Health Sciences Center El Pa 5001 El Paso Drive El Paso TX 79905 752668018 501(C)(3) 8500 MSR The Children's Hospital of Philadelphia 34th Street and Civic Center Boulev Philadelphia PA 19104 231352166 501(C)(3) 50000 YIA The University of Alabama at Birmingham 1720 2nd Avenue South Birmingham AL 35233 636005396 501(C)(3) 200000 YIA The University of Chicago 5841 S Maryland Ave Chicago IL 60637 362177139 501(C)(3) 50000 YIA The University of North Carolina at Chapel Hill 102 Mason Farm Rd Chapel Hill NC 275997295 566001393 501(C)(3) 150000 YIA The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Houston TX 77030 746001118 501(C)(3) 700000 CDA, YIA Tufts University School of Medicine 136 Harrison Avenue Boston MA 021111817 042103634 501(C)(3) 8500 MSR UCSF Benioff Children's Hospital Oakland 747 52nd Street Oakland CA 94609 940382330 501(C)(3) 50000 YIA University of Arizona 888 N Euclid Ave Room 510 Tucson AZ 85719 742652689 501(C)(3) 8500 MSR University of California San Diego 3855 Health Sciences Drive La Jolla CA 92093 956006144 501(C)(3) 100000 YIA University of California Davis 1850 Research Park Dr Davis CA 95618 946036494 501(C)(3) 50000 YIA University of California San Francisco 2340 Sutter Street San Francisco CA 941150128 946036493 501(C)(3) 50000 YIA University of Minnesota 450 McNamara Alumni Center Minneapolis MN 55455 416007513 501(C)(3) 50000 YIA University of Pennsylvania 16th Floor Penn Tower Philadelphia PA 191044283 231352685 501(C)(3) 150000 YIA University of Pittsburgh 5150 Centre Avenue Pittsburgh PA 15232 250965591 501(C)(3) 250000 CDA, YIA University of South Alabama 307 University Blvd Mobile AL 366880002 630477348 501(C)(3) 8500 MSR University of Southern California 3720 S Flower St Los Angeles CA 900890701 951642394 501(C)(3) 50000 YIA University of Washington 4333 Brooklyn Ave NE Seattle WA 981959472 916001537 501(C)(3) 50000 YIA University of Wisconsin 21 N Park Street Madison WI 537151218 396006492 501(C)(3) 50000 YIA Washington University Campus Box 1054 St Louis MO 631304862 430653611 501(C)(3) 50000 YIA Winship Cancer Institute of Emory University 525 East 68th Street New York NY 10065 131623978 501(C)(3) 50000 YIA 46 Merit Awards 202 202000 Patient Advocate Scholarships 22 39600 Medical Student Rotation Award 23 87500 Resident Travel Award 6 9000 PART I, LINE 1 CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE TO CCF AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CONQUER CANCER REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CCF'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENTLY WITH THE APPROVED BUDGET. part II, award abbreviations: YIA: Young investigator award CDA: Career Development award MSR: Medical Student Rotation ACRA: Advanced Clinical REsearch award false false false false false false false false false Clifford Hudis MD FACP CEO 0 818627 0 79567 0 0 0 21000 0 3233 0 922427 0 Nancy Daly MS MPH EXEC VP & CHIEF PHILAN OFFICER 0 380173 0 7500 0 0 21000 0 17537 0 426210 0 0 LINDA JENSEN CPA CFO 0 394424 0 7500 0 0 21000 0 17536 0 440460 0 0 PART I, LINE 3: EXPLANATION: COMPENSATION IS ESTABLISHED BY A RELATED ORGANIZATION, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC. THE METHODS USED BY ASCO TO DETERMINE COMPENSATION ARE: COMPENSATION COMMITTEE; INDEPENDENT COMPENSATION CONSULTANT; FORMS 990 OF OTHER ORGANIZATIONS, WRITTEN EMPLOYMENT CONTRACT; COMPENSATION STUDY OR SURVEY; AND APPROVAL BY BOARD OR COMPENSATION COMMITTEE. X 2 1525 FMV X 18 1889349 FMV X VARIOUS SILENT AUCTION ITEMS 60 104648 FMV false true false FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES PATIENT EDUCATION AND INFORMATION - WELL-INFORMED, EDUCATED PATIENTS ARE THEIR OWN BEST ADVOCATES, AS WELL AS INVALUABLE PARTNERS FOR DOCTORS. CONQUER CANCER SUPPORTS PROGRAMS AND ACCURATE, DOCTOR-APPROVED CANCER INFORMATION AND RESOURCES BOTH IN PRINT AND ONLINE, THAT EDUCATE PATIENTS AND THE PUBLIC ABOUT CANCER CARE, TREATMENT, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. FUNDING IN THIS AREA ALLOWS CONQUER CANCER TO CONTINUE AND EXPAND OUR WORK TO INFORM PATIENTS. HIGHLIGHTS OF PATIENT EDUCATION AND INFORMATION PROGRAMS AND ACTIVITIES SUPPORTED BY CONQUER CANCER IN 2019 INCLUDE THE FOLLOWING: PATIENT ADVOCATE SCHOLARSHIP PROGRAM- THE PATIENT ADVOCATE SCHOLARSHIP PROGRAM PROVIDES THE OPPORTUNITY FOR ADVOCATES TO ATTEND ASCOS SCIENTIFIC MEETINGS TO GAIN THE EDUCATION, KNOWLEDGE, AND SKILLS NECESSARY TO PARTICIPATE IN PATIENT ADVOCACY AND THE CANCER RESEARCH PROCESS. THE SCHOLARSHIPS ALSO ENABLE ADVOCATES TO PROMOTE THEIR ORGANIZATIONS PROGRAMS, SERVICES, AND RESOURCES AND TO NETWORK WITH ONE ANOTHER AS WELL AS WITH ONCOLOGY PROFESSIONALS. IN 2019, $186,284 IN FUNDING ALLOWED 65 PATIENT ADVOCATES TO ATTEND THE ASCO MEETINGS. CANCER.NET- CANCER.NET BRINGS THE EXPERTISE AND RESOURCES OF ASCO TO PEOPLE LIVING WITH CANCER AND THOSE WHO CARE FOR AND CARE ABOUT THEM. THE WEBSITE PROVIDES TIMELY, COMPREHENSIVE INFORMATION TO HELP PATIENTS AND FAMILIES MAKE INFORMED HEALTH CARE DECISIONS. ALL CONTENT IS SUBJECT TO A FORMAL PEER-REVIEW PROCESS BY THE CANCER.NET EDITORIAL BOARD, COMPOSED OF MORE THAN 150 MEDICAL, SURGICAL, RADIATION, AND PEDIATRIC ONCOLOGISTS, PHYSICIAN ASSISTANTS, ONCOLOGY NURSES, SOCIAL WORKERS, AND PATIENT ADVOCATES AND INCLUDES PEER-REVIEWED INFORMATION ON MORE THAN 120 TYPES OF CANCER AND SYNDROMES, INCLUDING RISK FACTORS, DIAGNOSIS, FINDING AN ONCOLOGIST, TREATMENT, MANAGING SIDE EFFECTS, CLINICAL TRIALS, AND AFTER TREATMENT, CAREGIVING, COPING STRATEGIES, AND SURVIVORSHIP. INFORMATION IS DELIVERED IN WRITTEN ARTICLES, VIDEOS, AND AUDIO PODCASTS. THIS INFORMATION IS MADE AVAILABLE FREE TO THE PUBLIC. FORM 990, PART VI, SECTION A, LINE 1 AS OF DECEMBER 31, 2018, THE BOARD OF DIRECTORS OF CONQUER CANCER INCLUDED SIXTEEN (16) DIRECTORS WITH VOTING RIGHTS, AND TWO (2) WITHOUT VOTING RIGHTS. ALL VOTING MEMBERS OF THE BOARD OF DIRECTORS HAVE THE SAME VOTING RIGHTS. DURING THE REPORTED TAX YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS CONSISTENT WITH CONQUER CANCER'S BYLAWS. THE EXECUTIVE COMMITTEE IS COMPOSED OF SIX MEMBERS OF THE BOARD OF DIRECTORS, WHO ARE THE CHAIR OF THE BOARD OF DIRECTORS, THE CEO, THE SECRETARY, THE TREASURER, THE EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHOPIC OFFICER (NON-VOTING), AND A SIXTH DIRECTOR WHO IS NOMINATED BY THE CHAIR OF THE BOARD AND ELECTED BY A MAJORITY OF THE VOTING MEMBERS OF THE BOARD OF DIRECTORS. ALL OF THE MEMBERS OF THE EXECUTIVE COMMITTEE EXCEPT THE EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER ARE ENTITLED TO VOTE. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY CONQUER CANCER'S BYLAWS, WHICH PROVIDE THAT EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW AND EXCEPT AS SPECIFIED IN THE BYLAWS, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD MEETING. ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH CONQUER CANCER'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 2 DR. CLIFFORD HUDIS, NANCY DALY, AND LINDA JENSEN WERE ALL EMPLOYED BY ASCO. DR. CLIFFORD HUDIS, DR. HOWARD BURRIS, AND DR. THOMAS ROBERTS, JR. ALL SERVED ON THE ASCO BOARD OF DIRECTORS DURING 2019. FORM 990, PART VI, SECTION A, LINE 7A CONQUER CANCER DOES NOT HAVE MEMBERS. DIRECTORS OF CONQUER CANCER ARE APPOINTED AND SUBJECT TO REMOVAL BY THE BOARD OF DIRECTORS OF ASCO, EXCEPT FOR DIRECTORS SERVING EX-OFFICIO. FORM 990, PART VI, SECTION A, LINE 7B THE BOARD OF DIRECTORS OF CONQUER CANCER MAY VOTE TO AMEND OR REPEAL THE BYLAWS OF CONQUER CANCER, BUT THE BOARD OF DIRECTORS OF ASCO MUST APPROVE AN AMENDMENT OR REPEAL OF THE BYLAWS TO BE EFFECTIVE. CONQUER CANCER MAY NOT AMEND ITS ARTICLES OF INCORPORATION WITHOUT PROVIDING TO ASCO WRITTEN NOTICE OF THE PROPOSED AMENDMENT AT LEAST THIRTY (30) DAYS IN ADVANCE. FORM 990, PART VI, SECTION B, LINE 11B AN ELECTRONIC COPY OF THE CONQUER CANCER FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS BEFORE IT WAS FILED. THE CONQUER CANCER FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER, THE EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER, THE CEO, AND THE GENERAL COUNSEL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C CONQUER CANCER MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL CONQUER CANCER STAFF, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G., SPOUSE, DEPENDENT CHILDREN). UNDER CONQUER CANCER'S POLICIES, COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS,CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE, AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. CONQUER CANCER'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, WHEN CONQUER CANCER IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY "INTERESTED PERSON" (I.E., A CONQUER CANCER DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINES 15A & 15B THE FOLLOWING EMPLOYEES OF ASCO SERVE AS OFFICERS OF CONQUER CANCER: CEO OF CONQUER CANCER (ALSO SERVES AS CEO OF ASCO) EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER OF CONQUER CANCER CFO OF CONQUER CANCER INFORMATION REGARDING THEIR COMPENSATION AND THE PROCESS FOR DETERMINING THEIR COMPENSATION ARE DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER STAFF ARE EMPLOYEES OF ASCO WHO ARE LEASED TO CONQUER CANCER. APPLICABLE INFORMATION REGARDING THEIR COMPENSATION IS DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER DOES NOT PAY COMPENSATION TO THESE INDIVIDUALS. FORM 990, PART VI, SECTION C, LINE 19 CONQUER CANCER'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. CONQUER CANCER'S ARTICLES OF INCORPORATION ARE ALSO AVAILABLE TO THE PUBLIC THROUGH THE VIRGINIA STATE CORPORATION COMMISSION. CONFLICT OF INTEREST POLICIES AND STANDARDS ARE POSTED ON CONQUER CANCER'S WEBSITE. THE ANNUAL REPORT OF CONQUER CANCER IS POSTED ON CONQUER CANCER'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS OF CONQUER CANCER ARE POSTED ON CONQUER CANCER'S WEBSITE. AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 MILL RD 800 ALEXANDRIA VA 22314 136180380 education NY 501(C)(3) 10 NA false ASCO ASSOCIATION 2318 MILL ROAD ALEXANDRIA VA 22314 833561693 MEMBER SERV. VA 501(C)(6) ASCO false false true true true false false false false false false true true true true true true true false false